The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Tenaya Therapeutics, Inc. | COM | 87990A106 | 52,924 | 9,400,290 | SH | SOLE | 9,400,290 | 0 | 0 | ||
| Revolution Medicines Inc | COM | 76155X100 | 85,660 | 4,395,050 | SH | SOLE | 4,395,050 | 0 | 0 | ||
| RAPT Therapeutics Inc | COM | 75382E109 | 48,918 | 2,680,458 | SH | SOLE | 2,680,458 | 0 | 0 | ||
| ORIC Pharmaceuticals Inc. | COM | 68622P109 | 15,985 | 3,568,181 | SH | SOLE | 3,568,181 | 0 | 0 | ||
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 232,513 | 18,136,735 | SH | SOLE | 18,136,735 | 0 | 0 | ||
| Surrozen, Inc. | COM | 86889P109 | 27,745 | 9,248,129 | SH | SOLE | 9,248,129 | 0 | 0 | ||
| eFFECTOR Therapeutics Inc | COM | 28202V108 | 6,119 | 4,309,329 | SH | SOLE | 4,309,329 | 0 | 0 | ||